| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammary Glands, Animal | 31 | 2016 | 65 | 6.570 |
Why?
|
| Macaca fascicularis | 74 | 2024 | 434 | 5.870 |
Why?
|
| Macaca mulatta | 37 | 2024 | 305 | 4.190 |
Why?
|
| Animals | 160 | 2024 | 7510 | 4.080 |
Why?
|
| Isoflavones | 17 | 2013 | 81 | 3.350 |
Why?
|
| Radiation Injuries | 6 | 2023 | 76 | 3.070 |
Why?
|
| Estradiol | 17 | 2022 | 136 | 2.960 |
Why?
|
| Whole-Body Irradiation | 10 | 2024 | 53 | 2.780 |
Why?
|
| Postmenopause | 28 | 2013 | 430 | 2.720 |
Why?
|
| Soybeans | 13 | 2013 | 35 | 2.530 |
Why?
|
| Breast | 11 | 2024 | 68 | 2.410 |
Why?
|
| Soybean Proteins | 11 | 2016 | 74 | 2.330 |
Why?
|
| Estrogens, Conjugated (USP) | 21 | 2022 | 140 | 2.210 |
Why?
|
| Estrogen Replacement Therapy | 16 | 2022 | 199 | 2.180 |
Why?
|
| Radiation Injuries, Experimental | 8 | 2024 | 36 | 2.090 |
Why?
|
| Medroxyprogesterone Acetate | 17 | 2012 | 102 | 2.070 |
Why?
|
| Ovariectomy | 34 | 2021 | 166 | 2.030 |
Why?
|
| Monkey Diseases | 7 | 2016 | 20 | 1.910 |
Why?
|
| Female | 126 | 2024 | 19999 | 1.880 |
Why?
|
| Uterus | 16 | 2019 | 103 | 1.880 |
Why?
|
| Receptors, Progesterone | 17 | 2015 | 72 | 1.860 |
Why?
|
| Breast Neoplasms | 15 | 2021 | 765 | 1.830 |
Why?
|
| Estrogens | 17 | 2024 | 180 | 1.750 |
Why?
|
| Endometrium | 14 | 2016 | 180 | 1.700 |
Why?
|
| Receptors, Estrogen | 18 | 2021 | 113 | 1.570 |
Why?
|
| Norpregnenes | 11 | 2013 | 22 | 1.460 |
Why?
|
| Progesterone | 9 | 2009 | 101 | 1.340 |
Why?
|
| Cell Proliferation | 18 | 2019 | 604 | 1.330 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2012 | 34 | 1.280 |
Why?
|
| Cerebrovascular Disorders | 2 | 2020 | 52 | 1.250 |
Why?
|
| Testis | 3 | 2023 | 65 | 1.190 |
Why?
|
| Disease Models, Animal | 16 | 2024 | 1020 | 1.180 |
Why?
|
| Diet | 11 | 2016 | 390 | 1.180 |
Why?
|
| Brain | 7 | 2023 | 948 | 1.150 |
Why?
|
| Estrogen Receptor alpha | 9 | 2024 | 52 | 1.150 |
Why?
|
| Brain Injuries | 2 | 2018 | 92 | 1.120 |
Why?
|
| Vagina | 4 | 2012 | 59 | 1.040 |
Why?
|
| Tamoxifen | 7 | 2014 | 59 | 1.010 |
Why?
|
| Prostate | 3 | 2022 | 68 | 0.980 |
Why?
|
| Hormone Replacement Therapy | 9 | 2021 | 91 | 0.960 |
Why?
|
| Endometrial Neoplasms | 5 | 2011 | 49 | 0.960 |
Why?
|
| Sexual Maturation | 4 | 2016 | 25 | 0.950 |
Why?
|
| Immunohistochemistry | 17 | 2016 | 534 | 0.940 |
Why?
|
| Hypercapnia | 1 | 2023 | 4 | 0.920 |
Why?
|
| Male | 53 | 2024 | 19202 | 0.920 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 38 | 0.900 |
Why?
|
| Spermatogonia | 1 | 2023 | 14 | 0.890 |
Why?
|
| Extracellular Matrix | 4 | 2018 | 245 | 0.890 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 493 | 0.880 |
Why?
|
| Radiation Dosage | 5 | 2024 | 84 | 0.880 |
Why?
|
| Apoptosis | 12 | 2024 | 353 | 0.880 |
Why?
|
| Models, Animal | 9 | 2023 | 169 | 0.870 |
Why?
|
| Gene Expression | 11 | 2018 | 337 | 0.860 |
Why?
|
| Primates | 6 | 2023 | 108 | 0.860 |
Why?
|
| Lung Injury | 2 | 2023 | 68 | 0.850 |
Why?
|
| Gamma Rays | 3 | 2019 | 25 | 0.850 |
Why?
|
| Humans | 57 | 2024 | 32082 | 0.830 |
Why?
|
| Menopause | 6 | 2011 | 95 | 0.830 |
Why?
|
| Cerebrovascular Circulation | 2 | 2023 | 93 | 0.820 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2022 | 8 | 0.810 |
Why?
|
| Phytoestrogens | 8 | 2016 | 23 | 0.810 |
Why?
|
| Random Allocation | 15 | 2018 | 227 | 0.780 |
Why?
|
| Sarcoma | 1 | 2022 | 73 | 0.760 |
Why?
|
| Progestins | 4 | 2021 | 22 | 0.750 |
Why?
|
| Genitalia, Female | 5 | 2006 | 9 | 0.740 |
Why?
|
| Anticarcinogenic Agents | 3 | 2009 | 25 | 0.740 |
Why?
|
| Kidney | 4 | 2023 | 518 | 0.720 |
Why?
|
| Dose-Response Relationship, Radiation | 9 | 2023 | 81 | 0.720 |
Why?
|
| Placenta | 4 | 2013 | 74 | 0.720 |
Why?
|
| Organ Size | 13 | 2024 | 218 | 0.680 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2023 | 917 | 0.670 |
Why?
|
| Selective Estrogen Receptor Modulators | 6 | 2013 | 36 | 0.670 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 53 | 0.660 |
Why?
|
| Genistein | 3 | 2009 | 15 | 0.650 |
Why?
|
| Endometriosis | 3 | 2018 | 99 | 0.650 |
Why?
|
| Contraceptives, Oral | 3 | 2008 | 23 | 0.650 |
Why?
|
| Neoplasms | 4 | 2024 | 728 | 0.640 |
Why?
|
| Fibronectins | 1 | 2018 | 36 | 0.630 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 63 | 0.610 |
Why?
|
| Ki-67 Antigen | 10 | 2015 | 30 | 0.610 |
Why?
|
| Mice | 26 | 2024 | 2474 | 0.600 |
Why?
|
| Insulin Resistance | 5 | 2020 | 461 | 0.590 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 156 | 0.580 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 2012 | 29 | 0.580 |
Why?
|
| Uterine Neoplasms | 2 | 2015 | 27 | 0.570 |
Why?
|
| Reproduction | 4 | 2019 | 15 | 0.560 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 93 | 0.550 |
Why?
|
| Estrogens, Non-Steroidal | 4 | 2001 | 6 | 0.550 |
Why?
|
| Testosterone | 2 | 2023 | 48 | 0.540 |
Why?
|
| Decidua | 1 | 2016 | 18 | 0.540 |
Why?
|
| Estrogen Antagonists | 3 | 2012 | 17 | 0.540 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 308 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 1325 | 0.540 |
Why?
|
| Epilepsy | 1 | 2017 | 82 | 0.520 |
Why?
|
| Cell Differentiation | 3 | 2016 | 469 | 0.510 |
Why?
|
| Menstrual Cycle | 2 | 2006 | 61 | 0.500 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2010 | 42 | 0.490 |
Why?
|
| Coronary Vessels | 8 | 2024 | 165 | 0.480 |
Why?
|
| Cognition Disorders | 2 | 2015 | 385 | 0.460 |
Why?
|
| Body Weight | 8 | 2022 | 309 | 0.450 |
Why?
|
| Cognition | 2 | 2016 | 556 | 0.450 |
Why?
|
| Puberty | 1 | 2013 | 7 | 0.450 |
Why?
|
| Mammary Neoplasms, Animal | 4 | 2006 | 14 | 0.450 |
Why?
|
| Fallopian Tube Neoplasms | 2 | 2024 | 9 | 0.440 |
Why?
|
| Ethinyl Estradiol | 3 | 2010 | 9 | 0.430 |
Why?
|
| Syndecan-1 | 3 | 2012 | 11 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2017 | 1428 | 0.430 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 96 | 0.410 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 263 | 0.410 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 67 | 0.400 |
Why?
|
| Contraceptive Agents, Female | 2 | 2008 | 16 | 0.390 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2011 | 11 | 0.390 |
Why?
|
| Premenopause | 4 | 2012 | 44 | 0.390 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 322 | 0.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2009 | 261 | 0.370 |
Why?
|
| Administration, Oral | 6 | 2009 | 187 | 0.360 |
Why?
|
| Plant Preparations | 5 | 2004 | 27 | 0.360 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2024 | 81 | 0.350 |
Why?
|
| Receptors, Androgen | 2 | 2019 | 47 | 0.350 |
Why?
|
| Androgens | 2 | 2009 | 30 | 0.350 |
Why?
|
| Endometrial Hyperplasia | 2 | 2013 | 14 | 0.340 |
Why?
|
| Coronary Artery Disease | 3 | 2024 | 401 | 0.340 |
Why?
|
| RNA, Messenger | 6 | 2016 | 507 | 0.340 |
Why?
|
| Homeostasis | 3 | 2018 | 132 | 0.340 |
Why?
|
| Receptors, Steroid | 4 | 2012 | 9 | 0.330 |
Why?
|
| Mammography | 1 | 2009 | 41 | 0.330 |
Why?
|
| Macaca | 4 | 2012 | 27 | 0.330 |
Why?
|
| Soy Foods | 1 | 2009 | 7 | 0.330 |
Why?
|
| Uterine Diseases | 2 | 2007 | 22 | 0.320 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 637 | 0.320 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 4 | 0.320 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 4 | 0.320 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2008 | 6 | 0.320 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 34 | 0.320 |
Why?
|
| Caspases | 2 | 2005 | 36 | 0.320 |
Why?
|
| Multienzyme Complexes | 2 | 2005 | 18 | 0.310 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2008 | 6 | 0.310 |
Why?
|
| Pyrrolidines | 1 | 2008 | 12 | 0.310 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 124 | 0.310 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2008 | 20 | 0.310 |
Why?
|
| Heart | 3 | 2019 | 176 | 0.310 |
Why?
|
| Vitamin D | 2 | 2024 | 184 | 0.310 |
Why?
|
| Papillomaviridae | 2 | 2007 | 22 | 0.300 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 64 | 0.300 |
Why?
|
| Stress, Psychological | 2 | 2013 | 222 | 0.300 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2007 | 36 | 0.300 |
Why?
|
| Apolipoproteins E | 2 | 2021 | 95 | 0.290 |
Why?
|
| Transcription, Genetic | 4 | 2019 | 137 | 0.290 |
Why?
|
| Infarction | 1 | 2007 | 6 | 0.290 |
Why?
|
| Fibrosis | 3 | 2020 | 120 | 0.290 |
Why?
|
| Hormones | 1 | 2007 | 22 | 0.290 |
Why?
|
| Social Behavior | 1 | 2007 | 65 | 0.290 |
Why?
|
| Risk | 2 | 2020 | 321 | 0.290 |
Why?
|
| Epithelial Cells | 6 | 2013 | 141 | 0.280 |
Why?
|
| Pregnancy | 8 | 2019 | 996 | 0.280 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 160 | 0.280 |
Why?
|
| Prostatic Neoplasms | 4 | 2015 | 471 | 0.280 |
Why?
|
| Genes, erbB-2 | 3 | 2012 | 6 | 0.280 |
Why?
|
| Carcinoma, Ductal | 1 | 2006 | 1 | 0.280 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2006 | 4 | 0.270 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 15 | 0.270 |
Why?
|
| Child, Preschool | 4 | 2023 | 1267 | 0.270 |
Why?
|
| Mice, Knockout | 6 | 2020 | 443 | 0.270 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 105 | 0.270 |
Why?
|
| Environmental Pollutants | 1 | 2006 | 21 | 0.270 |
Why?
|
| Benzopyrans | 1 | 2006 | 6 | 0.270 |
Why?
|
| Hyperplasia | 6 | 2014 | 41 | 0.260 |
Why?
|
| Hypertrophy | 2 | 2024 | 27 | 0.260 |
Why?
|
| Histocytochemistry | 4 | 2013 | 31 | 0.260 |
Why?
|
| Papilloma | 2 | 2010 | 9 | 0.260 |
Why?
|
| Pterocarpans | 3 | 2011 | 5 | 0.250 |
Why?
|
| Cervical Intraepithelial Neoplasia | 2 | 2007 | 4 | 0.250 |
Why?
|
| Rats | 8 | 2015 | 1592 | 0.250 |
Why?
|
| Thorax | 2 | 2023 | 29 | 0.250 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 92 | 0.250 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 55 | 0.250 |
Why?
|
| Proliferating Cell Nuclear Antigen | 4 | 2009 | 31 | 0.250 |
Why?
|
| Lung | 3 | 2023 | 249 | 0.250 |
Why?
|
| Motor Activity | 1 | 2007 | 324 | 0.250 |
Why?
|
| Risk Factors | 7 | 2012 | 3880 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2023 | 81 | 0.240 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 4 | 0.240 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2024 | 13 | 0.240 |
Why?
|
| Fatty Liver | 1 | 2005 | 66 | 0.240 |
Why?
|
| Aromatase | 1 | 2024 | 10 | 0.240 |
Why?
|
| Mice, Transgenic | 8 | 2024 | 261 | 0.240 |
Why?
|
| Obesity | 3 | 2020 | 1176 | 0.240 |
Why?
|
| Vaginal Neoplasms | 1 | 2004 | 1 | 0.240 |
Why?
|
| Femur | 1 | 2024 | 74 | 0.230 |
Why?
|
| Alcohol Drinking | 2 | 2004 | 255 | 0.230 |
Why?
|
| Cross-Over Studies | 4 | 2008 | 95 | 0.230 |
Why?
|
| Adult | 6 | 2023 | 9375 | 0.230 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2015 | 57 | 0.230 |
Why?
|
| Genitalia, Male | 1 | 2004 | 4 | 0.230 |
Why?
|
| Acute Radiation Syndrome | 1 | 2023 | 3 | 0.230 |
Why?
|
| Iohexol | 1 | 2023 | 8 | 0.230 |
Why?
|
| Genital Neoplasms, Female | 1 | 2004 | 17 | 0.230 |
Why?
|
| Spin Labels | 1 | 2023 | 24 | 0.230 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2023 | 14 | 0.230 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 581 | 0.230 |
Why?
|
| Growth Hormone | 4 | 2010 | 15 | 0.230 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2023 | 29 | 0.230 |
Why?
|
| Sex Characteristics | 2 | 2024 | 173 | 0.230 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 147 | 0.230 |
Why?
|
| Estrogen Receptor beta | 3 | 2009 | 13 | 0.230 |
Why?
|
| Adolescent | 5 | 2024 | 3568 | 0.220 |
Why?
|
| Hypertension | 2 | 2022 | 961 | 0.220 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 1128 | 0.220 |
Why?
|
| Signal Transduction | 5 | 2014 | 680 | 0.220 |
Why?
|
| Time Factors | 7 | 2019 | 2145 | 0.220 |
Why?
|
| Protein Isoforms | 2 | 2020 | 57 | 0.210 |
Why?
|
| Indoles | 2 | 2013 | 56 | 0.210 |
Why?
|
| Child | 4 | 2023 | 2439 | 0.210 |
Why?
|
| Coronary Disease | 2 | 2001 | 211 | 0.210 |
Why?
|
| Receptors, Calcitriol | 2 | 2012 | 9 | 0.210 |
Why?
|
| Reference Values | 2 | 2022 | 246 | 0.210 |
Why?
|
| Lymphocytes | 1 | 2022 | 57 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 91 | 0.210 |
Why?
|
| Papillomavirus Infections | 3 | 2010 | 67 | 0.200 |
Why?
|
| Area Under Curve | 2 | 2020 | 93 | 0.200 |
Why?
|
| Aging | 4 | 2022 | 943 | 0.200 |
Why?
|
| Caspase 3 | 3 | 2008 | 31 | 0.200 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2021 | 4 | 0.200 |
Why?
|
| Pelger-Huet Anomaly | 1 | 2021 | 1 | 0.200 |
Why?
|
| Monocytes | 2 | 2022 | 127 | 0.200 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 288 | 0.200 |
Why?
|
| Ovary | 3 | 2011 | 58 | 0.200 |
Why?
|
| Ethanol | 1 | 2004 | 189 | 0.200 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3505 | 0.200 |
Why?
|
| Young Adult | 4 | 2023 | 2665 | 0.190 |
Why?
|
| Middle Aged | 6 | 2023 | 11834 | 0.190 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2014 | 12 | 0.190 |
Why?
|
| Lactalbumin | 2 | 2012 | 10 | 0.190 |
Why?
|
| Caseins | 2 | 2012 | 14 | 0.190 |
Why?
|
| Analysis of Variance | 3 | 2008 | 462 | 0.190 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 71 | 0.190 |
Why?
|
| Amygdala | 1 | 2021 | 61 | 0.190 |
Why?
|
| Drug Combinations | 5 | 2013 | 98 | 0.190 |
Why?
|
| Osteoporosis | 1 | 2001 | 70 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 198 | 0.190 |
Why?
|
| Adipose Tissue | 2 | 2022 | 349 | 0.180 |
Why?
|
| Calibration | 1 | 2020 | 28 | 0.180 |
Why?
|
| Endocrine Disruptors | 1 | 2019 | 1 | 0.180 |
Why?
|
| Body Size | 1 | 2020 | 34 | 0.180 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 60 | 0.170 |
Why?
|
| Carcinogens | 3 | 2009 | 35 | 0.170 |
Why?
|
| Blastomyces | 1 | 1999 | 2 | 0.170 |
Why?
|
| Blastomycosis | 1 | 1999 | 3 | 0.170 |
Why?
|
| Aged | 4 | 2023 | 10308 | 0.170 |
Why?
|
| Atherosclerosis | 3 | 2024 | 766 | 0.170 |
Why?
|
| Lactation | 2 | 2011 | 16 | 0.170 |
Why?
|
| ROC Curve | 1 | 2020 | 163 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 6 | 0.170 |
Why?
|
| Mice, Inbred Strains | 2 | 2013 | 48 | 0.170 |
Why?
|
| Cyclooxygenase 2 | 2 | 2011 | 48 | 0.170 |
Why?
|
| Hematopoietic System | 1 | 2019 | 3 | 0.170 |
Why?
|
| Immunity | 1 | 2019 | 20 | 0.160 |
Why?
|
| Diphtheria Toxin | 3 | 2004 | 26 | 0.160 |
Why?
|
| Epithelium | 4 | 2004 | 31 | 0.160 |
Why?
|
| Myocardium | 2 | 2018 | 185 | 0.160 |
Why?
|
| Emergency Treatment | 1 | 1999 | 42 | 0.160 |
Why?
|
| Progesterone Congeners | 3 | 2003 | 18 | 0.160 |
Why?
|
| Clonidine | 1 | 1999 | 62 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2009 | 629 | 0.160 |
Why?
|
| Incidence | 1 | 2022 | 1199 | 0.160 |
Why?
|
| Diastole | 1 | 2018 | 96 | 0.160 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 214 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 42 | 0.160 |
Why?
|
| Cell Line | 4 | 2019 | 435 | 0.160 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 36 | 0.160 |
Why?
|
| Blood Cells | 1 | 2018 | 9 | 0.150 |
Why?
|
| Plants, Edible | 1 | 1998 | 2 | 0.150 |
Why?
|
| Vinyl Compounds | 2 | 2009 | 9 | 0.150 |
Why?
|
| Placebos | 2 | 2008 | 63 | 0.150 |
Why?
|
| Administration, Intravaginal | 2 | 2007 | 9 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2005 | 276 | 0.150 |
Why?
|
| Liver | 3 | 2008 | 484 | 0.150 |
Why?
|
| Macrophages | 2 | 2018 | 188 | 0.150 |
Why?
|
| Microvessels | 1 | 2017 | 24 | 0.150 |
Why?
|
| DNA Damage | 1 | 2018 | 99 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2008 | 57 | 0.150 |
Why?
|
| Body Composition | 2 | 2019 | 396 | 0.140 |
Why?
|
| Antioxidants | 1 | 1998 | 114 | 0.140 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 101 | 0.140 |
Why?
|
| Prolactin | 2 | 2008 | 10 | 0.140 |
Why?
|
| Cytokines | 1 | 2018 | 256 | 0.140 |
Why?
|
| Receptors, Opioid | 1 | 2016 | 11 | 0.140 |
Why?
|
| Age Factors | 3 | 2024 | 1187 | 0.140 |
Why?
|
| Calcium | 1 | 2018 | 306 | 0.140 |
Why?
|
| Chemokines | 1 | 2016 | 35 | 0.140 |
Why?
|
| Toxicology | 2 | 2013 | 6 | 0.140 |
Why?
|
| Cell Division | 4 | 2004 | 99 | 0.140 |
Why?
|
| Haplorhini | 3 | 2012 | 68 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 118 | 0.140 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 80 | 0.130 |
Why?
|
| Mutation, Missense | 2 | 2014 | 50 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2016 | 142 | 0.130 |
Why?
|
| Muscle, Skeletal | 3 | 2017 | 512 | 0.130 |
Why?
|
| Logistic Models | 2 | 2009 | 783 | 0.130 |
Why?
|
| Gene Deletion | 2 | 2014 | 66 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2016 | 189 | 0.130 |
Why?
|
| Bone Density | 3 | 2024 | 205 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 1999 | 352 | 0.130 |
Why?
|
| Mammary Glands, Human | 2 | 2015 | 15 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2016 | 119 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2015 | 181 | 0.130 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2013 | 25 | 0.130 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 10 | 0.130 |
Why?
|
| Inflammation | 2 | 2016 | 529 | 0.130 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 21 | 0.130 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 26 | 0.130 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 133 | 0.130 |
Why?
|
| Myometrium | 2 | 2014 | 11 | 0.120 |
Why?
|
| Citric Acid | 1 | 2014 | 6 | 0.120 |
Why?
|
| Hirudins | 1 | 2014 | 19 | 0.120 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 48 | 0.120 |
Why?
|
| Platelet Aggregation | 1 | 2014 | 21 | 0.120 |
Why?
|
| Interleukin-3 | 2 | 2004 | 11 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 45 | 0.120 |
Why?
|
| Myoblasts, Skeletal | 1 | 2015 | 19 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2014 | 39 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2015 | 49 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2015 | 103 | 0.120 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 44 | 0.120 |
Why?
|
| Blood Cell Count | 3 | 2019 | 29 | 0.120 |
Why?
|
| Heparin | 1 | 2014 | 73 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 70 | 0.120 |
Why?
|
| Nitroimidazoles | 1 | 1994 | 4 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 104 | 0.120 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2015 | 65 | 0.120 |
Why?
|
| DNA Adducts | 1 | 2014 | 12 | 0.120 |
Why?
|
| Dog Diseases | 1 | 1994 | 11 | 0.120 |
Why?
|
| Cell Hypoxia | 1 | 1994 | 41 | 0.110 |
Why?
|
| Lipids | 6 | 2016 | 232 | 0.110 |
Why?
|
| Glucose | 1 | 2015 | 174 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 374 | 0.110 |
Why?
|
| Urethra | 1 | 2015 | 102 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2013 | 4 | 0.110 |
Why?
|
| Rats, Inbred Strains | 1 | 2013 | 45 | 0.110 |
Why?
|
| Mast Cells | 1 | 2013 | 12 | 0.110 |
Why?
|
| Fallopian Tubes | 2 | 2024 | 9 | 0.110 |
Why?
|
| Lidocaine | 1 | 2013 | 17 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 52 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 24 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2013 | 23 | 0.110 |
Why?
|
| Toxicity Tests | 1 | 2013 | 13 | 0.110 |
Why?
|
| Adenosine | 1 | 2013 | 58 | 0.110 |
Why?
|
| Heart Arrest | 1 | 2013 | 38 | 0.110 |
Why?
|
| Pathology | 1 | 2013 | 17 | 0.110 |
Why?
|
| Frameshift Mutation | 1 | 2012 | 6 | 0.110 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 209 | 0.110 |
Why?
|
| Receptors, Thyrotropin-Releasing Hormone | 1 | 2012 | 1 | 0.110 |
Why?
|
| Receptors, Thyrotropin | 1 | 2012 | 2 | 0.110 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2012 | 2 | 0.110 |
Why?
|
| Animals, Wild | 1 | 2012 | 2 | 0.110 |
Why?
|
| Animals, Zoo | 1 | 2012 | 2 | 0.110 |
Why?
|
| Primate Diseases | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2012 | 4 | 0.110 |
Why?
|
| Cell Transformation, Viral | 1 | 2012 | 8 | 0.110 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 49 | 0.110 |
Why?
|
| Metagenome | 1 | 2012 | 5 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2013 | 65 | 0.100 |
Why?
|
| DDT | 1 | 2012 | 2 | 0.100 |
Why?
|
| DNA | 1 | 2014 | 226 | 0.100 |
Why?
|
| Intestines | 1 | 2012 | 61 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 4 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 71 | 0.100 |
Why?
|
| Aggression | 2 | 2012 | 30 | 0.100 |
Why?
|
| Cyclohexenes | 2 | 2009 | 13 | 0.100 |
Why?
|
| Genes, ras | 3 | 2015 | 26 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 148 | 0.100 |
Why?
|
| Skin | 1 | 2014 | 211 | 0.100 |
Why?
|
| Choristoma | 1 | 2011 | 17 | 0.100 |
Why?
|
| Cyclooxygenase 1 | 1 | 2011 | 22 | 0.100 |
Why?
|
| PPAR gamma | 2 | 2008 | 46 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 71 | 0.100 |
Why?
|
| Biological Availability | 1 | 2011 | 21 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2011 | 1427 | 0.100 |
Why?
|
| Cervix Uteri | 2 | 2008 | 28 | 0.090 |
Why?
|
| Betapapillomavirus | 1 | 2010 | 1 | 0.090 |
Why?
|
| Skin Diseases, Viral | 1 | 2010 | 4 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 22 | 0.090 |
Why?
|
| Ligaments | 1 | 2010 | 13 | 0.090 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Tyrosine | 1 | 2010 | 23 | 0.090 |
Why?
|
| Ovarian Follicle | 2 | 2009 | 30 | 0.090 |
Why?
|
| Horses | 2 | 2002 | 15 | 0.090 |
Why?
|
| Cholecalciferol | 2 | 2024 | 21 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2011 | 185 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2008 | 60 | 0.090 |
Why?
|
| Hippocampus | 1 | 2011 | 170 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2008 | 2282 | 0.090 |
Why?
|
| Molecular Structure | 1 | 2009 | 59 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 510 | 0.080 |
Why?
|
| Drug Antagonism | 1 | 2009 | 1 | 0.080 |
Why?
|
| Women's Health | 1 | 2011 | 235 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2011 | 3304 | 0.080 |
Why?
|
| Histological Techniques | 2 | 2011 | 7 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 2009 | 55 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 244 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2009 | 65 | 0.080 |
Why?
|
| Cricetulus | 1 | 2008 | 12 | 0.080 |
Why?
|
| Diet Surveys | 1 | 2009 | 57 | 0.080 |
Why?
|
| Cricetinae | 1 | 2008 | 39 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 725 | 0.080 |
Why?
|
| CpG Islands | 1 | 2008 | 45 | 0.080 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2008 | 33 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2013 | 62 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2019 | 107 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 94 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2013 | 835 | 0.080 |
Why?
|
| PPAR alpha | 1 | 2008 | 29 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 103 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 21 | 0.080 |
Why?
|
| Urothelium | 1 | 2008 | 55 | 0.080 |
Why?
|
| Adenoma | 1 | 2008 | 35 | 0.080 |
Why?
|
| Heterozygote | 2 | 2005 | 59 | 0.080 |
Why?
|
| Mutation | 2 | 2014 | 485 | 0.080 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 8 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2013 | 167 | 0.080 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2007 | 5 | 0.080 |
Why?
|
| Epidermis | 1 | 2007 | 30 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2009 | 923 | 0.070 |
Why?
|
| Rabbits | 2 | 2008 | 197 | 0.070 |
Why?
|
| Keratins | 1 | 2007 | 39 | 0.070 |
Why?
|
| Leptin | 2 | 2020 | 71 | 0.070 |
Why?
|
| Depression | 1 | 2011 | 445 | 0.070 |
Why?
|
| Sperm Count | 1 | 2007 | 2 | 0.070 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 30 | 0.070 |
Why?
|
| Oncogenic Viruses | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cell Aging | 1 | 2007 | 2 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 448 | 0.070 |
Why?
|
| Breast Diseases | 1 | 2007 | 4 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2007 | 57 | 0.070 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 8 | 0.070 |
Why?
|
| Organogenesis | 1 | 2007 | 16 | 0.070 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2007 | 5 | 0.070 |
Why?
|
| Species Specificity | 2 | 2019 | 90 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2006 | 5 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2008 | 182 | 0.070 |
Why?
|
| Oncogenes | 1 | 2006 | 13 | 0.070 |
Why?
|
| Estrone | 1 | 2006 | 8 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 357 | 0.070 |
Why?
|
| DNA Primers | 2 | 2004 | 91 | 0.070 |
Why?
|
| Disease Progression | 4 | 2015 | 594 | 0.070 |
Why?
|
| Phenotype | 3 | 2016 | 632 | 0.070 |
Why?
|
| Ferritins | 1 | 2006 | 47 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2006 | 46 | 0.070 |
Why?
|
| Biological Markers | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 764 | 0.060 |
Why?
|
| Iron | 1 | 2006 | 116 | 0.060 |
Why?
|
| Gene Therapy | 1 | 2005 | 1 | 0.060 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2005 | 3 | 0.060 |
Why?
|
| Peptides | 1 | 2006 | 120 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 412 | 0.060 |
Why?
|
| Angiotensin I | 1 | 2007 | 241 | 0.060 |
Why?
|
| Follicular Phase | 1 | 2004 | 11 | 0.060 |
Why?
|
| Alternative Splicing | 2 | 2015 | 30 | 0.060 |
Why?
|
| Insulin | 4 | 2014 | 367 | 0.060 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 41 | 0.060 |
Why?
|
| Luteal Phase | 1 | 2004 | 29 | 0.060 |
Why?
|
| Dominance-Subordination | 1 | 2004 | 16 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2005 | 98 | 0.060 |
Why?
|
| Adrenal Cortex | 1 | 2004 | 3 | 0.060 |
Why?
|
| Radiometry | 1 | 2024 | 40 | 0.060 |
Why?
|
| Dogs | 2 | 2015 | 120 | 0.060 |
Why?
|
| Pericardium | 1 | 2024 | 52 | 0.060 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2023 | 3 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2007 | 398 | 0.060 |
Why?
|
| Ligands | 1 | 2023 | 81 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2004 | 78 | 0.060 |
Why?
|
| Norethindrone | 1 | 2003 | 2 | 0.060 |
Why?
|
| Estradiol Congeners | 1 | 2003 | 3 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2023 | 107 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2005 | 229 | 0.060 |
Why?
|
| Mitochondria | 1 | 2005 | 185 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2023 | 111 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 2004 | 123 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2003 | 43 | 0.050 |
Why?
|
| Dwarfism | 1 | 2002 | 5 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 414 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 308 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 283 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 667 | 0.050 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 101 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 159 | 0.050 |
Why?
|
| Feces | 1 | 2022 | 38 | 0.050 |
Why?
|
| Adipocytes | 1 | 2022 | 81 | 0.050 |
Why?
|
| Coronary Angiography | 3 | 2013 | 153 | 0.050 |
Why?
|
| Lipoproteins | 2 | 2001 | 86 | 0.050 |
Why?
|
| Cell Movement | 2 | 2012 | 169 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2014 | 11 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 92 | 0.050 |
Why?
|
| Carbohydrate Metabolism | 1 | 2001 | 17 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 2 | 2013 | 8 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2001 | 54 | 0.040 |
Why?
|
| Tumor Markers, Biological | 1 | 2000 | 1 | 0.040 |
Why?
|
| Receptors, sigma | 1 | 2000 | 4 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2001 | 76 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 105 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2001 | 225 | 0.040 |
Why?
|
| Lipolysis | 1 | 2019 | 18 | 0.040 |
Why?
|
| Base Sequence | 2 | 2012 | 252 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 41 | 0.040 |
Why?
|
| Fetal Development | 1 | 2019 | 26 | 0.040 |
Why?
|
| Colony-Stimulating Factors | 1 | 1999 | 1 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2019 | 494 | 0.040 |
Why?
|
| Microspheres | 1 | 1999 | 44 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2020 | 147 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2019 | 16 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2013 | 290 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1999 | 83 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 6 | 0.040 |
Why?
|
| Health Status | 1 | 2002 | 400 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pneumonia | 1 | 1999 | 67 | 0.040 |
Why?
|
| Spleen | 1 | 1999 | 87 | 0.040 |
Why?
|
| Phylogeny | 2 | 2010 | 56 | 0.040 |
Why?
|
| Megestrol | 1 | 1998 | 1 | 0.040 |
Why?
|
| Norpregnadienes | 1 | 1998 | 1 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2019 | 33 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2019 | 46 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 122 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2018 | 16 | 0.040 |
Why?
|
| Methylcholanthrene | 1 | 1998 | 6 | 0.040 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1998 | 6 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Point Mutation | 1 | 1998 | 28 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 1999 | 124 | 0.040 |
Why?
|
| Immunity, Innate | 2 | 2013 | 75 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2010 | 228 | 0.040 |
Why?
|
| Micronucleus Tests | 1 | 2018 | 4 | 0.040 |
Why?
|
| Vasodilation | 1 | 1998 | 94 | 0.040 |
Why?
|
| Nandrolone | 1 | 1998 | 1 | 0.040 |
Why?
|
| Anabolic Agents | 1 | 1998 | 1 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 876 | 0.040 |
Why?
|
| Terpenes | 1 | 1998 | 7 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1998 | 8 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2018 | 81 | 0.040 |
Why?
|
| Carotenoids | 1 | 1998 | 10 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2018 | 42 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 23 | 0.040 |
Why?
|
| Neurons | 1 | 2021 | 407 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 82 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2018 | 84 | 0.040 |
Why?
|
| Injections, Intramuscular | 2 | 2009 | 43 | 0.040 |
Why?
|
| Diet, Atherogenic | 2 | 2012 | 62 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2013 | 7 | 0.040 |
Why?
|
| Cholesterol | 2 | 2013 | 252 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 1997 | 7 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 164 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 215 | 0.040 |
Why?
|
| Equilin | 1 | 1996 | 2 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 75 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 157 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 190 | 0.030 |
Why?
|
| Microglia | 1 | 2016 | 57 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1996 | 123 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 827 | 0.030 |
Why?
|
| Glucose Tolerance Test | 2 | 2009 | 126 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2015 | 31 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2014 | 13 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 1998 | 476 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 88 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2004 | 62 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 770 | 0.030 |
Why?
|
| Erythrocebus patas | 1 | 2014 | 1 | 0.030 |
Why?
|
| Codon | 1 | 2014 | 9 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2014 | 17 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 42 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2014 | 122 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 2013 | 6 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 225 | 0.030 |
Why?
|
| Brain Death | 1 | 2013 | 26 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 46 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 16 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2013 | 3 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2013 | 4 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 21 | 0.030 |
Why?
|
| Propanolamines | 1 | 2013 | 11 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2013 | 23 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 31 | 0.030 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2012 | 1 | 0.030 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2012 | 2 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 28 | 0.030 |
Why?
|
| Animal Experimentation | 1 | 2012 | 5 | 0.030 |
Why?
|
| Epinephrine | 1 | 2013 | 40 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 61 | 0.030 |
Why?
|
| Swine | 1 | 2013 | 215 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 72 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2013 | 71 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 59 | 0.030 |
Why?
|
| Protein Transport | 1 | 2012 | 74 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 122 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 125 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2013 | 49 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2013 | 155 | 0.030 |
Why?
|
| Oxygen | 1 | 2013 | 142 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2004 | 171 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 146 | 0.030 |
Why?
|
| Creatinine | 1 | 2013 | 196 | 0.030 |
Why?
|
| Social Isolation | 1 | 2012 | 45 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 742 | 0.030 |
Why?
|
| Energy Intake | 1 | 2012 | 128 | 0.030 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2011 | 15 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2011 | 28 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 259 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 604 | 0.020 |
Why?
|
| Vasoconstriction | 2 | 2003 | 43 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2012 | 156 | 0.020 |
Why?
|
| Foot | 1 | 2010 | 39 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 23 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2010 | 3 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 33 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 895 | 0.020 |
Why?
|
| Hand | 1 | 2010 | 66 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2010 | 47 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 80 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 62 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 98 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2010 | 92 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 60 | 0.020 |
Why?
|
| Fructosamine | 1 | 2009 | 5 | 0.020 |
Why?
|
| Animal Feed | 1 | 2009 | 16 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 247 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 201 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 225 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 288 | 0.020 |
Why?
|
| Myositis | 1 | 2009 | 10 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2009 | 45 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 547 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 2008 | 14 | 0.020 |
Why?
|
| Vacuoles | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cytoplasmic Granules | 1 | 2008 | 7 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 13 | 0.020 |
Why?
|
| Chromans | 1 | 2008 | 5 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 47 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2007 | 29 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 208 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 9 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2007 | 114 | 0.020 |
Why?
|
| Endoscopy | 1 | 2007 | 58 | 0.020 |
Why?
|
| Doxycycline | 1 | 2006 | 26 | 0.020 |
Why?
|
| Hela Cells | 1 | 2006 | 79 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 31 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2006 | 81 | 0.020 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2004 | 5 | 0.020 |
Why?
|
| Anorexia | 1 | 2004 | 5 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 23 | 0.020 |
Why?
|
| Vasculitis | 1 | 2004 | 24 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 100 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 48 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2003 | 72 | 0.010 |
Why?
|
| Dobutamine | 1 | 2003 | 68 | 0.010 |
Why?
|
| Aorta | 1 | 2003 | 126 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 201 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2002 | 118 | 0.010 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 9 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2002 | 83 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 77 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1998 | 48 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 6 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1998 | 43 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 62 | 0.010 |
Why?
|
| Raloxifene | 1 | 1997 | 1 | 0.010 |
Why?
|
| Vasomotor System | 1 | 1996 | 22 | 0.010 |
Why?
|
| Piperidines | 1 | 1997 | 118 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 392 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 1496 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1996 | 107 | 0.010 |
Why?
|